葛兰素史克(GSK)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

GSK 葛兰素史克

交易中 12-15 11:36:48 EST

49.12

+0.31

+0.64%

最高49.33	最低48.90	成交量225.76万
今开48.90	昨收48.81	日振幅0.88%
总市值1,001亿	流通市值956.31亿	总股本20.38亿
成交额1.11亿	换手率0.12%	流通股本19.47亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"GSK","market":"US","secType":"STK","nameCN":"葛兰素史克","latestPrice":49.12,"timestamp":1765816606676,"preClose":48.81,"halted":0,"volume":2257581,"delay":0,"floatShares":1946891708,"shares":2038406200,"eps":3.572046,"marketStatus":"交易中","change":0.31,"latestTime":"12-15 11:36:48 EST","open":48.9,"high":49.33,"low":48.9,"amount":111072149.89502999,"amplitude":0.00881,"askPrice":49.12,"askSize":741,"bidPrice":49.11,"bidSize":10,"shortable":3,"etf":0,"ttmEps":3.572046,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1765832400000},"marketStatusCode":2,"adr":1,"adrRate":2,"listingDate":977893200000,"exchange":"NYSE","adjPreClose":48.81,"dividendRate":0.034833,"preHourTrading":{"tag":"盘前","latestPrice":48.88,"preClose":48.81,"latestTime":"09:29 EST","volume":1068911,"amount":52257333.567646,"timestamp":1765808999761},"postHourTrading":{"tag":"盘后","latestPrice":48.93,"preClose":48.81,"latestTime":"19:29 EST","volume":68857,"amount":3360952.62,"timestamp":1765585760888},"volumeRatio":1.929089,"impliedVol":0.2423,"impliedVolPercentile":0.12},"requestUrl":"/m/hq/s/GSK","defaultTab":"news","newsList":[{"id":"2582936115","title":"AN2治疗公司与GSK达成合作，共同推进基于硼的结核病治疗方法的发展AN2 Therapeutics Enters into Collaboration with GSK to Advance Boronased Therapies for Tuberculosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2582936115","media":"动脉网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582936115?lang=zh_cn&edition=full","pubTime":"2025-11-11 14:19","pubTimestamp":1762841940,"startTime":"0","endTime":"0","summary":"AN2 Therapeutics has entered into a research collaboration with GSK to develop new treatments for tuberculosis .AN2 Therapeutics与GSK达成了一项研究合作，以开发治疗结核病的新疗法。经验证的LeuRS靶点是多种化合物的基础，包括用于治疗NTM肺病的在研药物epetraborole、用于治疗结核病的在研药物ganfeborole，以及获得FDA批准的抗真菌药物tavaborole。This collaboration builds on previous work between AN2’s team and GSK’s Global Health research and development group. It represents a joint effort to explore innovative approaches that could help address the growing burden of TB, particularly in low-income countries.这项合作建立在AN2团队与GSK全球健康研发小组之前的工作基础之上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111114212194fcffac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111114212194fcffac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","GSK.UK","GSK","LENZ","BK4588","ANTX","BK4585","BK4007","BK4532","LU1829250122.USD","BK4539"],"gpt_icon":0},{"id":"2582608828","title":"探索“功能性治愈”新路径，展望“无乙肝的未来”","url":"https://stock-news.laohu8.com/highlight/detail?id=2582608828","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582608828?lang=zh_cn&edition=full","pubTime":"2025-11-10 15:45","pubTimestamp":1762760739,"startTime":"0","endTime":"0","summary":"在第八届中国国际进口博览会上，葛兰素史克（GSK）举办了以“为了没有乙肝的未来”为主题的医学专场活动，聚焦慢性乙型肝炎（CHB）防治与“功能性治愈”的前沿突破，探讨乙肝防治的最新科研进展与未来诊疗格局的变革。从控制到治愈：乙肝防治进入“存量管理”新阶段我国乙肝防治历经三十余年努力，疫苗接种构筑起坚实防线，使新发感染率显著下降。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://biz.eastmoney.com/a/202511103559749093.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4532","CHB","GSK.UK","GSK","BK4588","BK4200","ASO","BK4561","LU1829250122.USD","BK4585","BK4007"],"gpt_icon":0},{"id":"2581185388","title":"GSK深化“医防协同”实践：如何实现慢病管理与带疱预防的“双向奔赴”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2581185388","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581185388?lang=zh_cn&edition=full","pubTime":"2025-11-08 09:06","pubTimestamp":1762563964,"startTime":"0","endTime":"0","summary":"11月5日至10日，第八届中国国际进口博览会（下称“进博会”）在上海如期举行。全球领先的生物医药企业葛兰素史克（GSK）以“合力超越，创健未来”为主题参展，首次全新呈现“防治结合、全生命周期”的健康解决方案布局，彰显其深耕中国市场的决心。在此次展出的创新产品与解决方案中，欣安立适的亮相再次引发关注——作为国内首个重组带状疱疹疫苗，此前刚斩获重大突破。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511083558838393.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511083558838393.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["GSK.UK","LU1829250122.USD","BK4585","BK4588","BK4007","BK4532","GSK"],"gpt_icon":0},{"id":"2581907867","title":"小摩：将葛兰素史克目标价上调至1500便士","url":"https://stock-news.laohu8.com/highlight/detail?id=2581907867","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581907867?lang=zh_cn&edition=full","pubTime":"2025-11-07 13:57","pubTimestamp":1762495021,"startTime":"0","endTime":"0","summary":"摩根大通将葛兰素史克目标价从1400便士上调至1500便士。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20251107/31776033.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["GSK"],"gpt_icon":0},{"id":"2581432022","title":"GSK：呼吁建立规范化的全国系统性红斑狼疮诊疗体系，助力狼疮患者改善预后","url":"https://stock-news.laohu8.com/highlight/detail?id=2581432022","media":"国际金融报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581432022?lang=zh_cn&edition=full","pubTime":"2025-11-07 12:19","pubTimestamp":1762489192,"startTime":"0","endTime":"0","summary":"在第八届中国国际进口博览会（以下简称“进博会”）上，葛兰素史克（GSK）成功邀请多位风湿免疫领域资深专家、学者、公益组织伙伴齐聚一堂，共同围绕系统性红斑狼疮（SLE）的疾病认知、患者支持与慢病管理等议题展开交流，旨在提升公众科学认知、改善患者生存环境，助力患者重拾生活信心。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511073558114960.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511073558114960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["GSK.UK","BK4585","BK4532","BK4588","GSK","BK4007","LU1829250122.USD"],"gpt_icon":0},{"id":"2581559023","title":"进博盛宴：跨国药械创新出击，本土合作全面开花","url":"https://stock-news.laohu8.com/highlight/detail?id=2581559023","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581559023?lang=zh_cn&edition=full","pubTime":"2025-11-07 09:09","pubTimestamp":1762477753,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者季媛媛韩利明上海报道医疗健康行业正以惊人韧性应对时代变局。2024年全球市场强势增长9%——专科治疗突破创新、抗肥胖药物爆发式增长、AI医疗应用广泛落地，共同缔造了这场行业盛宴。前行之路机遇与挑战并存，需要我们洞察快速变化的市场动态，把握新药上市机遇，紧跟新型治疗领域的飞速发展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511073557886071.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511073557886071.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["GSK.UK","BK4585","BK4532","LU1829250122.USD","SLE","BK4077","GSK","BK4588","BK4007"],"gpt_icon":0},{"id":"2581050496","title":"葛兰素史克连续八年参展进博会","url":"https://stock-news.laohu8.com/highlight/detail?id=2581050496","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581050496?lang=zh_cn&edition=full","pubTime":"2025-11-06 17:42","pubTimestamp":1762422149,"startTime":"0","endTime":"0","summary":"北京商报讯11月6日，第八届中国国际进口博览会（以下简称“进博会”）葛兰素史克（以下简称“GSK”）展台正式揭幕，今年GSK以“合力超越，创健未来”为主题，展台呈现了其在防治结合、全生命周期健康管理方面的布局和理念。据悉，这已经是GSK连续八年参展进博会。本届进博会上，GSK带来了多款创新管线产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511063557136575.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511063557136575.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["GSK.UK","LU1829250122.USD","BK4588","BK4585","GSK","BK4532","BK4007"],"gpt_icon":0},{"id":"2581086859","title":"何为进博｜新朋老友再聚首，“东方之约”承载了哪些期待？","url":"https://stock-news.laohu8.com/highlight/detail?id=2581086859","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581086859?lang=zh_cn&edition=full","pubTime":"2025-11-06 07:02","pubTimestamp":1762383720,"startTime":"0","endTime":"0","summary":"与往届相比，本届进博会有155个国家、地区和国际组织参与，4108家境外企业参展，整体展览面积超过43万平方米，规模再创新高。进博会承载了各方期待，充分彰显中国超大规模市场的蓬勃生机和活力。作为进博会“全勤生”，美敦力受益匪浅。本届进博会上，10余款“溢出效应”的代表产品再次亮相。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2025-11-06/doc-infwmepi2278705.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-11-06/doc-infwmepi2278705.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["GSK.UK","BK4585","BK4532","LU1829250122.USD","GSK","BK4588","BK4007"],"gpt_icon":0},{"id":"2581716653","title":"新一轮流感席卷而来 全球第二大流感疫苗生产商押注美国接种反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=2581716653","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581716653?lang=zh_cn&edition=full","pubTime":"2025-11-05 11:46","pubTimestamp":1762314383,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，全球第二大流感疫苗生产商CSL Ltd.最新业绩预测数据显示，随着全球卫生团体对错误信息进行反击以及与新一轮全球流感之下与流感病毒密切相关联的疾病发病率迅速上升重新唤起全球卫生健康工作者们对预防流感的关注，美国市场的流感疫苗接种规模将出现大幅反弹。该公司表示，来自各大政府部门的预购协议相关费用将在流感大流行的第一波流感疫苗接种浪潮期间帮助产生约35亿美元的营收规模。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1365412.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1829250122.USD","GSK.UK","GSK","BK4585","BK4532","BK4007","BK4588"],"gpt_icon":0},{"id":"2580443846","title":"化学老师出身的她，凭啥成为中国最富有的女人？","url":"https://stock-news.laohu8.com/highlight/detail?id=2580443846","media":"雷达财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580443846?lang=zh_cn&edition=full","pubTime":"2025-11-01 08:24","pubTimestamp":1761956687,"startTime":"0","endTime":"0","summary":"10月28日，随着胡润研究院发布的《2025胡润百富榜》，新一届中国女首富正式揭晓。今年，翰森制药董事会主席、首席执行官钟慧娟和女儿孙远以1410亿元的身家，成功取代宗馥莉，荣登新一届中国女首富宝座。同花顺iFinD显示，截至上半年末，钟慧娟及其女儿孙远合计持有翰森制药65.61%的股份。2025年上半年，以创新药阿美乐为代表的抗肿瘤产品表现卓越，为翰森制药贡献收入约45.31亿元，占公司总收入的约六成，成为公司营收的重要支柱。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8nv309TQk2f","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"ifeng_tech","symbols":["BK4585","LU1023057109.AUD","LU0359202008.SGD","BK1161","01276","BK1589","BK1515","BK4588","GSK.UK","BK1574","LU0359201612.USD","03692","BK1583","06978","BK1191","BK4532","LU2543165471.USD","LU0359201885.HKD","GSK","BK4007","09939","LU1829250122.USD"],"gpt_icon":0},{"id":"2579902554","title":"葛兰素史克业绩超预期并上调全年展望","url":"https://stock-news.laohu8.com/highlight/detail?id=2579902554","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579902554?lang=zh_cn&edition=full","pubTime":"2025-10-29 21:54","pubTimestamp":1761746070,"startTime":"0","endTime":"0","summary":"葛兰素史克（GSK）股价上涨6.1%，此前该公司宣布业绩超出预期，并提高全年业绩展望。该公司报告其特种药物和疫苗部门均实现强劲销售增长。GSK现在预计2025年营业额将增长6%至7%，核心营业利润和每股收益增长预期也均被上调。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-10-29/doc-infvqmni0148616.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["BK4007","BK4532","GSK.UK","LU1829250122.USD","GSK","BK4585","BK4588"],"gpt_icon":0},{"id":"1162316316","title":"异动解读 | 葛兰素史克盘中大涨5.31%，业绩超预期且上调全年指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1162316316","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162316316?lang=zh_cn&edition=full","pubTime":"2025-10-29 21:36","pubTimestamp":1761744993,"startTime":"0","endTime":"0","summary":"葛兰素史克今日盘中大涨5.31%，股价走势强劲。这一显著涨幅主要受到公司第三季度财报超预期以及上调全年业绩指引的推动。营收达85.5亿英镑，同比增长4.9%，超出分析师预期3亿英镑。这一调整反映了公司对其业务前景的乐观态度，特别是在艾滋病毒药物、免疫学药物和疫苗业务方面的持续增长。分析人士认为，葛兰素史克的强劲业绩表现和积极展望将有助于公司在即将迎来新任首席执行官的背景下保持增长势头。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ef522f117157951d640983c1fa6537a4","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["GSK"],"gpt_icon":1},{"id":"1181179157","title":"异动解读 | 葛兰素史克盘前大涨5.06%，Q3业绩超预期并上调全年指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1181179157","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181179157?lang=zh_cn&edition=full","pubTime":"2025-10-29 21:26","pubTimestamp":1761744392,"startTime":"0","endTime":"0","summary":"葛兰素史克股价今日盘前大涨5.06%，投资者对公司第三季度业绩表现和上调全年指引反应积极。根据公司最新发布的财报，葛兰素史克第三季度业绩超出市场预期。营收达85.5亿英镑，同比增长4.9%，超出分析师预期3亿英镑。分析人士认为，葛兰素史克的业绩表现和积极展望将有助于提升投资者信心，特别是在即将迎来新任首席执行官的背景下。葛兰素史克正通过早期阶段交易来加强其产品线，以应对这一挑战。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ef522f117157951d640983c1fa6537a4","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["GSK"],"gpt_icon":1},{"id":"2579223039","title":"艾滋与免疫药物需求强劲，葛兰素史克上调全年业绩指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2579223039","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579223039?lang=zh_cn&edition=full","pubTime":"2025-10-29 17:05","pubTimestamp":1761728748,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，得益于其艾滋病毒和免疫学药物需求的增长，葛兰素史克上调了全年利润和销售预期。葛兰素史克的特种药物产品组合，包括针对艾滋病毒、癌症以及狼疮等疾病的免疫学药物，预计将推动增长。与本地竞争对手阿斯利康不同，葛兰素史克尚未与特朗普政府达成协议，该协议旨在通过降价来换取免受行业关税等新规影响。葛兰素史克表示，全年指引已考虑了现行关税以及欧洲可能实施的15%关税的影响。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1361993.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK4532","BK4588","GSK","BK4007","LU1829250122.USD"],"gpt_icon":0},{"id":"2579592288","title":"葛兰素史克欧股上涨3.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579592288","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579592288?lang=zh_cn&edition=full","pubTime":"2025-10-29 16:20","pubTimestamp":1761726014,"startTime":"0","endTime":"0","summary":"葛兰素史克欧股上涨3.9%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202510293548438921.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510293548438921.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["GSK.UK","LU1829250122.USD","BK4585","GSK","BK4007","BK4532","BK4588"],"gpt_icon":0},{"id":"1105822524","title":"葛兰素史克Q3业绩超预期，上调全年核心每股收益增长指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1105822524","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105822524?lang=zh_cn&edition=full","pubTime":"2025-10-29 15:09","pubTimestamp":1761721745,"startTime":"0","endTime":"0","summary":"10月29日，$葛兰素史克(GSK)$美股夜盘涨近3%！第三季度业绩超预期，上调全年核心每股收益增长指引。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ef522f117157951d640983c1fa6537a4","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"葛兰素史克Q3业绩超预期，上调全年核心每股收益增长指引","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK","GSK.UK"],"gpt_icon":0},{"id":"2578628861","title":"葛兰素史克与Syndivia达成药物开发和商业化权利协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2578628861","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578628861?lang=zh_cn&edition=full","pubTime":"2025-10-27 22:45","pubTimestamp":1761576300,"startTime":"0","endTime":"0","summary":"美股周一早盘，葛兰素史克（GSK）股价上涨1.9%，此前该公司宣布已与Syndivia达成协议，获得其用于转移性去势抵抗性前列腺癌（mCRPC）的临床前抗体药物偶联物（ADC）的全球独家开发和商业化权利，潜在里程碑付款最高达2.68亿英镑。该协议丰富了葛兰素史克的肿瘤管线，重点关注晚期前列腺癌治疗。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-10-27/doc-infvkcqi1896442.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","BK4585","GSK","GSK.UK","BK4007","LU1829250122.USD","BK4532"],"gpt_icon":0},{"id":"2577548913","title":"美股异动 | 葛兰素史克(GSK.US)跌逾5% Blenrep适应症范围受限","url":"https://stock-news.laohu8.com/highlight/detail?id=2577548913","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577548913?lang=zh_cn&edition=full","pubTime":"2025-10-24 23:04","pubTimestamp":1761318250,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周五，葛兰素史克跌逾5%，报43.10美元。消息面上，瑞银分析师表示，GSK已获得美国食品药品监督管理局对其血液癌症药物Blenrep的批准，在一项曾存在不确定性的决定中取得了积极结果，但这一结果因该药物有限的适应症而略显黯淡。瑞银称，FDA批准Blenrep作为三线疗法——用于已接受过至少两种先前治疗的成年患者——而不是GSK希望的二线疗法。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1359780.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK4007","BK4585","LU1829250122.USD","BK4532","GSK.UK","GSK"],"gpt_icon":0},{"id":"2577157955","title":"再生元终止开发一款双靶点CAR-T；葛兰素史克BCMA ADC药物Blenrep获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2577157955","media":"氨基观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577157955?lang=zh_cn&edition=full","pubTime":"2025-10-24 19:55","pubTimestamp":1761306933,"startTime":"0","endTime":"0","summary":"葛兰素史克ADC药物死而复生。/ 03 /海外药闻1）再生元终止开发一款双靶点CAR-T10月23日，再生元决定放弃从2seventy bio收购的双靶点CAR-T疗法bbT369，该药物正在处于早期研究的剂量递增阶段中，用于评估治疗复发/难治性B细胞非霍奇金淋巴瘤患者。2）葛兰素史克BCMA ADC药物Blenrep获批上市10月23日，GSK宣布，美国FDA已批准其BCMA ADC药物Blenrep上市，联合硼替佐米和地塞米松，用于治疗至少接受过两种既往疗法的复发或难治性多发性骨髓瘤成年患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251024200649a6cc0bc6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251024200649a6cc0bc6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4080","BK4230","BK4007","GSK","BK4588","CAR","GSK.UK","LU1829250122.USD","BK4022","BK4532","ADC","BK4231","BK4585"],"gpt_icon":0},{"id":"2577152425","title":"华东医药、恒瑞新药在华上市，GSK重磅ADC在美上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2577152425","media":"医药经济报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577152425?lang=zh_cn&edition=full","pubTime":"2025-10-24 18:31","pubTimestamp":1761301916,"startTime":"0","endTime":"0","summary":"华东医药重磅新药获批上市10月24日，国家药监局官网显示，华东医药全资子公司杭州中美华东制药申报的1类新药马来酸美凡厄替尼片获批上市，适应症为：用于表皮生长因子受体21号外显子L858R置换突变的局部晚期或转移性非小细胞肺癌成人患者的一线治疗。GSK重磅ADC在美国获批上市当地时间10月23日，葛兰素史克宣布，BCMA ADC玛贝兰妥单抗已获得FDA批准上市。这也是全球首个获批上市的BCMA ADC。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251024184004a6cbe5b3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251024184004a6cbe5b3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01276","BK4231","BK4588","BK4080","BK4007","GSK.UK","LU1829250122.USD","BK4532","ADC","GSK","BK4585"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.gsk.com","stockEarnings":[{"period":"1week","weight":0.0083},{"period":"1month","weight":0.0154},{"period":"3month","weight":0.1954},{"period":"6month","weight":0.1946},{"period":"1year","weight":0.4284},{"period":"ytd","weight":0.4432}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"GSK Plc于1999年12月6日在英国成立的公众服务有限公司，是一个世界领先的研究型制药和保健公司，由 Glaxo Wellcome plc和SmithKline Beecham plc合并而成。公司致力于开发较现有治疗方案明显改善的新产品，为病人和政府、保险公司或其他第三方提供帮助。","yearOnYearQuotes":[{"month":1,"riseRate":0.577778,"avgChangeRate":0.012956},{"month":2,"riseRate":0.466667,"avgChangeRate":-0.001972},{"month":3,"riseRate":0.622222,"avgChangeRate":0.021018},{"month":4,"riseRate":0.673913,"avgChangeRate":0.032633},{"month":5,"riseRate":0.413043,"avgChangeRate":-0.008096},{"month":6,"riseRate":0.586957,"avgChangeRate":0.009648},{"month":7,"riseRate":0.543478,"avgChangeRate":0.003945},{"month":8,"riseRate":0.586957,"avgChangeRate":0.005806},{"month":9,"riseRate":0.521739,"avgChangeRate":0.005973},{"month":10,"riseRate":0.521739,"avgChangeRate":0.013062},{"month":11,"riseRate":0.478261,"avgChangeRate":0.009917},{"month":12,"riseRate":0.608696,"avgChangeRate":0.014083}],"exchange":"NYSE","name":"葛兰素史克","nameEN":"GlaxoSmithKline PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"葛兰素史克(GSK)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供葛兰素史克(GSK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"葛兰素史克,GSK,葛兰素史克股票,葛兰素史克股票老虎,葛兰素史克股票老虎国际,葛兰素史克行情,葛兰素史克股票行情,葛兰素史克股价,葛兰素史克股市,葛兰素史克股票价格,葛兰素史克股票交易,葛兰素史克股票购买,葛兰素史克股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"葛兰素史克(GSK)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供葛兰素史克(GSK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}